Eosinophilic and autoimmune gastrointestinal disease: new insights and new entities
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Philadelphia [u.a.]
Saunders
2008
|
| Schriftenreihe: | Gastroenterology clinics of North America
37,2 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XII S., S. 307 - 492 Ill., graph. Darst. |
| ISBN: | 1416058400 9781416058403 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV023387397 | ||
| 003 | DE-604 | ||
| 005 | 20150113 | ||
| 007 | t | ||
| 008 | 080709s2008 ad|| |||| 00||| eng d | ||
| 020 | |a 1416058400 |9 1-4160-5840-0 | ||
| 020 | |a 9781416058403 |9 978-1-4160-5840-3 | ||
| 035 | |a (OCoLC)233262198 | ||
| 035 | |a (DE-599)HBZHT015586173 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-19 |a DE-91 |a DE-29 | ||
| 082 | 0 | |a 616.33 |2 22 | |
| 245 | 1 | 0 | |a Eosinophilic and autoimmune gastrointestinal disease |b new insights and new entities |c guest ed. Nicholas J. Talley |
| 264 | 1 | |a Philadelphia [u.a.] |b Saunders |c 2008 | |
| 300 | |a XII S., S. 307 - 492 |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Gastroenterology clinics of North America |v 37,2 | |
| 650 | 4 | |a Autoimmune Diseases of the Gastrointestinal System | |
| 650 | 4 | |a Autoimmune diseases | |
| 650 | 4 | |a Celiac Disease | |
| 650 | 4 | |a Eosinophil disorders | |
| 650 | 4 | |a Eosinophils |x pathology | |
| 650 | 4 | |a Esophagitis | |
| 650 | 4 | |a Gastroenteritis | |
| 650 | 4 | |a Gastrointestinal Diseases | |
| 650 | 4 | |a Gastrointestinal Motility | |
| 650 | 4 | |a Gastrointestinal system |x Diseases | |
| 650 | 4 | |a Hepatitis, Autoimmune | |
| 650 | 4 | |a Inflammatory Bowel Diseases | |
| 650 | 4 | |a Liver Cirrhosis, Biliary | |
| 650 | 4 | |a Pancreatitis | |
| 700 | 1 | |a Talley, Nicholas J. |e Sonstige |0 (DE-588)135805074 |4 oth | |
| 830 | 0 | |a Gastroenterology clinics of North America |v 37,2 |w (DE-604)BV000613725 |9 37,2 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016570398&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-016570398 | ||
Datensatz im Suchindex
| _version_ | 1804137762878652416 |
|---|---|
| adam_text | CONTENTS VOLUME 37 » NUMBER 2 » JUNE 2008
Preface xi
Nicholas J. Talley
Gut Eosinophilia in Food Allergy and Systemic
and Autoimmune Diseases 307
Nicholas J. Talley
Eosinophilic gastroenteritis is a rare disease characterized by striking
tissue eosinophilia in any layer of the gut wall; however, many diseases
can cause increased gut eosinophilia. Allergic reactions to food are an
important cause of gut eosinophilia. Not all adverse reactions to food
are IgE mediated, and most cases of IgE-mediated food allergy do not
have eosinophilic gastroenteritis. Parasitic, bacterial, and viral padio-
gens as well as certain systemic diseases such as vasculitis can cause gut
eosinophilia. These heterogeneous conditions are reviewed in this
article.
Eosinophilic Gastroenteritis 333
Seema Khan and Susan R. Orenstein
Eosinophilic gastroenteritis is an infrequendy diagnosed condition drat
is characterized by prominent eosinophilic infiltration of the stomach or
small intestine, generally localized to one level of the intestinal wall; the
variable organ locus and wall depdi produce heterogeneous clinical
presentations. A strong association widi atopy is present in most cases,
supported by circumstantial evidence and die demonstration of Th-2
proinflammatory cytokine profiles in animal studies. A high degree of
suspicion is required to establish the diagnosis, which must be based on
intense gastrointestinal eosinophilia. Management is directed toward
removal of offending allergens and use of anti-inflammatory agents.
Novel and emerging treatments on die horizon are biologic dierapies
and selective anti-eosinophil agents.
Eosinophilic Esophagitis in Adults 349
Ganapathy A. Prasad and Nicholas J. Talley
Eosinophilic esophagitis in adults is a disease characterized by
eosinophilic infiltration of die esophageal mucosa and symptoms of
CONTENTS continued
long-standing solid food dysphagia and food impactions. First described
in 1978, this syndrome is being recognized increasingly in the
developed world, with multiple case series reported from the United
States, Europe, and Australia during die past decade. Diagnosis requires
the presence of greater than or equal to 15 eosinophils/high-power field
on esophageal biopsies. Successful treatment in adults has been reported
with the use of systemic and topical swallowed steroids. Endoscopic
treatment has been associated with increased an risk for tears and
perforations.
Eosinophilic Esophagitis in Children: Clinical
Manifestations 369
Philip E. Putnam
During the past decade, the increasing number of recognized cases of
eosinophilic esophagitis in children and adults has resulted in a dramatic
expansion of the medical literature surrounding it. Clinical and basic
research has contributed to a better, but still incomplete, body of
knowledge regarding its clinical and histologic manifestations, as well as
its immunologic and genetic pathogenesis. This article provides a broad
framework for recognizing the remarkable variety of clinical manifes¬
tations of eosinophilic esophagitis in children, which must be considered
as part of the differential diagnosis in many different clinical situations.
Functional Gastrointestinal Disorders
and the Potential Role of Eosinophils 383
Marjorie M. Walker and Nicholas J. Talley
The eosinophil-mast cell-neural pathway may be important in the
pathophysiology of functional gastrointestinal disorders characterized
by unexplained abdominal pain, disordered defecation, or meal-related
discomfort. There is evidence that duodenal eosinophils are increased
in functional dyspepsia, whereas mast cells are increased in the lower
gut in irritable bowel syndrome, directly supporting a role for
a hypersensitivity-type reaction in these disorders. The trigger may be
a pathogen, food, or other allergen in the gut mucosa. This trigger may
evoke eosinophils, mast cells, and other components to cascade to up-
regulate serotonin release, with modulation of the enteric and central
nervous systems, creating a vicious cycle. If correct, this theory suggests
treatment should specifically target the eosinophil-mast cell pathway.
Enteric Autoantibodies and Gut Motility Disorders 397
Purna Kashyap and Gianrico Farrugia
Increasing evidence suggests that a subset of gastrointestinal motility
disorders is associated with the presence of circulating antibodies. These
antibodies are directed against various molecular targets, the best
known being anti-neuronal nuclear antibody (ANNA-1 or anti-Hu)
associated widi paraneoplastic motility disorders. There is also evidence
that the presence of distinct autoantibody profiles is associated with
vi
CONTENTS continued
non-paraneoplastic motility disorders. This review focuses on the types
of antibodies associated with gastrointestinal motility disorders and die
significance of diese antibodies. Algorithms are suggested for the work-
up and treatment of patients widi circulating antibodies associated with
gastrointestinal motility disorders.
Celiac Disease and Autoimmunity in the Gut
and Elsewhere 411
Susan H. Barton and Joseph A. Murray
This review focuses on die autoimmune connective tissue diseases,
endocrine, and dermatologic conditions associated with celiac disease,
as well as die related gut inflammatory disorders of refractory celiac
disease, autoimmune enteropadiy, collagenous enteritis, and collage-
nous colitis.
(Auto)Antibodies in Inflammatory Bowel Diseases 429
Severine Vermeire, Nathalie Vermeulen, Gert Van Assche,
Xavier Bossuyt, and Paul Rutgeerts
Patients who have inflammatory bowel diseases (IBD) express strong
antibody responses to a variety of epitopes. A number of (auto)anti-
bodies have been described in patients who have Crohn s disease or
ulcerative colitis. These markers reflect a loss of tolerance toward
bacterial and fungal flora and have been studied for dieir clinical value
in IBD patients. However, currently, diey have no place in die
diagnostic work up. Their real promise may lie in dieir use as surrogate
markers of complicated aggressive disease as shown in various
retrospective studies, but prospective data are lacking.
Autoimmune Pancreatitis 439
Timothy B. Gardner and Suresh T. Chari
Autoimmune pancreatitis is die pancreatic manifestation of a systemic
disorder diat affects various organs, including die bile duct, retroper-
itoneum, kidney, and parotid and lacrimal glands. It represents
a recendy described subset of chronic pancreatitis diat is immune
mediated and has unique histologic, morphologic, and clinical
characteristics. A hallmark of die disease is its rapid response to
corticosteroid treatment. Akhough still a rare disease, autoimmune
pancreatitis is increasingly becoming recognized clinically, leading to
evolution in the understanding of its prognosis, clinical characteristics,
and treatment.
Diagnosis and Treatment of Autoimmune Hepatitis 461
Bruce A. Luxon
Autoimmune hepatitis (AIH) is an idiopadiic hepatitis characterized by
inflammation of die liver, presence of autoantibodies, and evidence of
increased gamma globulins in die serum. It represents an enigmatic
vii
CONTENTS continued
interaction between the immune system, autoantigens, and unknown
triggering factors. This article provides a brief summary of the diagnosis
of AIH, the natural history of ATH, an approach to the treatment and
follow-up of AIH, and the role of liver transplantation in the treatment
of Am.
Antimitochondrial Antibody-Negative Primary
Biliary Cirrhosis 479
Flavia Mendes and Keith D. Lindor
There is a subset of patients who have biochemical and histologic
features consistent with primary biliary cirrhosis (PBC) who lack
antimitochondrial antibodies (AMA). This entity is usually referred to
as AMA-negative PBC or alternatively autoimmune cholangitis.
Patients who have AMA-negative PBC are believed to have a similar
clinical course, response to treatment, and prognosis as their AMA-
positive counterparts. As more sensitive and specific serologic tests are
developed to detect serum AMA, it is possible we may find that these
patients initially believed to be AMA-negative are indeed AMA-positive,
suggesting a single disease process.
Index 485
viii
|
| adam_txt |
CONTENTS VOLUME 37 » NUMBER 2 » JUNE 2008
Preface xi
Nicholas J. Talley
Gut Eosinophilia in Food Allergy and Systemic
and Autoimmune Diseases 307
Nicholas J. Talley
Eosinophilic gastroenteritis is a rare disease characterized by striking
tissue eosinophilia in any layer of the gut wall; however, many diseases
can cause increased gut eosinophilia. Allergic reactions to food are an
important cause of gut eosinophilia. Not all adverse reactions to food
are IgE mediated, and most cases of IgE-mediated food allergy do not
have eosinophilic gastroenteritis. Parasitic, bacterial, and viral padio-
gens as well as certain systemic diseases such as vasculitis can cause gut
eosinophilia. These heterogeneous conditions are reviewed in this
article.
Eosinophilic Gastroenteritis 333
Seema Khan and Susan R. Orenstein
Eosinophilic gastroenteritis is an infrequendy diagnosed condition drat
is characterized by prominent eosinophilic infiltration of the stomach or
small intestine, generally localized to one level of the intestinal wall; the
variable organ locus and wall depdi produce heterogeneous clinical
presentations. A strong association widi atopy is present in most cases,
supported by circumstantial evidence and die demonstration of Th-2
proinflammatory cytokine profiles in animal studies. A high degree of
suspicion is required to establish the diagnosis, which must be based on
intense gastrointestinal eosinophilia. Management is directed toward
removal of offending allergens and use of anti-inflammatory agents.
Novel and emerging treatments on die horizon are biologic dierapies
and selective anti-eosinophil agents.
Eosinophilic Esophagitis in Adults 349
Ganapathy A. Prasad and Nicholas J. Talley
Eosinophilic esophagitis in adults is a disease characterized by
eosinophilic infiltration of die esophageal mucosa and symptoms of
CONTENTS continued
long-standing solid food dysphagia and food impactions. First described
in 1978, this syndrome is being recognized increasingly in the
developed world, with multiple case series reported from the United
States, Europe, and Australia during die past decade. Diagnosis requires
the presence of greater than or equal to 15 eosinophils/high-power field
on esophageal biopsies. Successful treatment in adults has been reported
with the use of systemic and topical swallowed steroids. Endoscopic
treatment has been associated with increased an risk for tears and
perforations.
Eosinophilic Esophagitis in Children: Clinical
Manifestations 369
Philip E. Putnam
During the past decade, the increasing number of recognized cases of
eosinophilic esophagitis in children and adults has resulted in a dramatic
expansion of the medical literature surrounding it. Clinical and basic
research has contributed to a better, but still incomplete, body of
knowledge regarding its clinical and histologic manifestations, as well as
its immunologic and genetic pathogenesis. This article provides a broad
framework for recognizing the remarkable variety of clinical manifes¬
tations of eosinophilic esophagitis in children, which must be considered
as part of the differential diagnosis in many different clinical situations.
Functional Gastrointestinal Disorders
and the Potential Role of Eosinophils 383
Marjorie M. Walker and Nicholas J. Talley
The eosinophil-mast cell-neural pathway may be important in the
pathophysiology of functional gastrointestinal disorders characterized
by unexplained abdominal pain, disordered defecation, or meal-related
discomfort. There is evidence that duodenal eosinophils are increased
in functional dyspepsia, whereas mast cells are increased in the lower
gut in irritable bowel syndrome, directly supporting a role for
a hypersensitivity-type reaction in these disorders. The trigger may be
a pathogen, food, or other allergen in the gut mucosa. This trigger may
evoke eosinophils, mast cells, and other components to cascade to up-
regulate serotonin release, with modulation of the enteric and central
nervous systems, creating a vicious cycle. If correct, this theory suggests
treatment should specifically target the eosinophil-mast cell pathway.
Enteric Autoantibodies and Gut Motility Disorders 397
Purna Kashyap and Gianrico Farrugia
Increasing evidence suggests that a subset of gastrointestinal motility
disorders is associated with the presence of circulating antibodies. These
antibodies are directed against various molecular targets, the best
known being anti-neuronal nuclear antibody (ANNA-1 or anti-Hu)
associated widi paraneoplastic motility disorders. There is also evidence
that the presence of distinct autoantibody profiles is associated with
vi
CONTENTS continued
non-paraneoplastic motility disorders. This review focuses on the types
of antibodies associated with gastrointestinal motility disorders and die
significance of diese antibodies. Algorithms are suggested for the work-
up and treatment of patients widi circulating antibodies associated with
gastrointestinal motility disorders.
Celiac Disease and Autoimmunity in the Gut
and Elsewhere 411
Susan H. Barton and Joseph A. Murray
This review focuses on die autoimmune connective tissue diseases,
endocrine, and dermatologic conditions associated with celiac disease,
as well as die related gut inflammatory disorders of refractory celiac
disease, autoimmune enteropadiy, collagenous enteritis, and collage-
nous colitis.
(Auto)Antibodies in Inflammatory Bowel Diseases 429
Severine Vermeire, Nathalie Vermeulen, Gert Van Assche,
Xavier Bossuyt, and Paul Rutgeerts
Patients who have inflammatory bowel diseases (IBD) express strong
antibody responses to a variety of epitopes. A number of (auto)anti-
bodies have been described in patients who have Crohn's disease or
ulcerative colitis. These markers reflect a loss of tolerance toward
bacterial and fungal flora and have been studied for dieir clinical value
in IBD patients. However, currently, diey have no place in die
diagnostic work up. Their real promise may lie in dieir use as surrogate
markers of complicated aggressive disease as shown in various
retrospective studies, but prospective data are lacking.
Autoimmune Pancreatitis 439
Timothy B. Gardner and Suresh T. Chari
Autoimmune pancreatitis is die pancreatic manifestation of a systemic
disorder diat affects various organs, including die bile duct, retroper-
itoneum, kidney, and parotid and lacrimal glands. It represents
a recendy described subset of chronic pancreatitis diat is immune
mediated and has unique histologic, morphologic, and clinical
characteristics. A hallmark of die disease is its rapid response to
corticosteroid treatment. Akhough still a rare disease, autoimmune
pancreatitis is increasingly becoming recognized clinically, leading to
evolution in the understanding of its prognosis, clinical characteristics,
and treatment.
Diagnosis and Treatment of Autoimmune Hepatitis 461
Bruce A. Luxon
Autoimmune hepatitis (AIH) is an idiopadiic hepatitis characterized by
inflammation of die liver, presence of autoantibodies, and evidence of
increased gamma globulins in die serum. It represents an enigmatic
vii
CONTENTS continued
interaction between the immune system, autoantigens, and unknown
triggering factors. This article provides a brief summary of the diagnosis
of AIH, the natural history of ATH, an approach to the treatment and
follow-up of AIH, and the role of liver transplantation in the treatment
of Am.
Antimitochondrial Antibody-Negative Primary
Biliary Cirrhosis 479
Flavia Mendes and Keith D. Lindor
There is a subset of patients who have biochemical and histologic
features consistent with primary biliary cirrhosis (PBC) who lack
antimitochondrial antibodies (AMA). This entity is usually referred to
as AMA-negative PBC or alternatively autoimmune cholangitis.
Patients who have AMA-negative PBC are believed to have a similar
clinical course, response to treatment, and prognosis as their AMA-
positive counterparts. As more sensitive and specific serologic tests are
developed to detect serum AMA, it is possible we may find that these
patients initially believed to be AMA-negative are indeed AMA-positive,
suggesting a single disease process.
Index 485
viii |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author_GND | (DE-588)135805074 |
| building | Verbundindex |
| bvnumber | BV023387397 |
| ctrlnum | (OCoLC)233262198 (DE-599)HBZHT015586173 |
| dewey-full | 616.33 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.33 |
| dewey-search | 616.33 |
| dewey-sort | 3616.33 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01856nam a2200481 cb4500</leader><controlfield tag="001">BV023387397</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20150113 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">080709s2008 ad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1416058400</subfield><subfield code="9">1-4160-5840-0</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781416058403</subfield><subfield code="9">978-1-4160-5840-3</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)233262198</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)HBZHT015586173</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield><subfield code="a">DE-91</subfield><subfield code="a">DE-29</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.33</subfield><subfield code="2">22</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Eosinophilic and autoimmune gastrointestinal disease</subfield><subfield code="b">new insights and new entities</subfield><subfield code="c">guest ed. Nicholas J. Talley</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Philadelphia [u.a.]</subfield><subfield code="b">Saunders</subfield><subfield code="c">2008</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XII S., S. 307 - 492</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Gastroenterology clinics of North America</subfield><subfield code="v">37,2</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Autoimmune Diseases of the Gastrointestinal System</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Autoimmune diseases</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Celiac Disease</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Eosinophil disorders</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Eosinophils</subfield><subfield code="x">pathology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Esophagitis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gastroenteritis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gastrointestinal Diseases</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gastrointestinal Motility</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gastrointestinal system</subfield><subfield code="x">Diseases</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hepatitis, Autoimmune</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Inflammatory Bowel Diseases</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Liver Cirrhosis, Biliary</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pancreatitis</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Talley, Nicholas J.</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)135805074</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Gastroenterology clinics of North America</subfield><subfield code="v">37,2</subfield><subfield code="w">(DE-604)BV000613725</subfield><subfield code="9">37,2</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016570398&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-016570398</subfield></datafield></record></collection> |
| id | DE-604.BV023387397 |
| illustrated | Illustrated |
| index_date | 2024-07-02T21:18:38Z |
| indexdate | 2024-07-09T21:17:27Z |
| institution | BVB |
| isbn | 1416058400 9781416058403 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-016570398 |
| oclc_num | 233262198 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM DE-91 DE-BY-TUM DE-29 |
| owner_facet | DE-19 DE-BY-UBM DE-91 DE-BY-TUM DE-29 |
| physical | XII S., S. 307 - 492 Ill., graph. Darst. |
| publishDate | 2008 |
| publishDateSearch | 2008 |
| publishDateSort | 2008 |
| publisher | Saunders |
| record_format | marc |
| series | Gastroenterology clinics of North America |
| series2 | Gastroenterology clinics of North America |
| spelling | Eosinophilic and autoimmune gastrointestinal disease new insights and new entities guest ed. Nicholas J. Talley Philadelphia [u.a.] Saunders 2008 XII S., S. 307 - 492 Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Gastroenterology clinics of North America 37,2 Autoimmune Diseases of the Gastrointestinal System Autoimmune diseases Celiac Disease Eosinophil disorders Eosinophils pathology Esophagitis Gastroenteritis Gastrointestinal Diseases Gastrointestinal Motility Gastrointestinal system Diseases Hepatitis, Autoimmune Inflammatory Bowel Diseases Liver Cirrhosis, Biliary Pancreatitis Talley, Nicholas J. Sonstige (DE-588)135805074 oth Gastroenterology clinics of North America 37,2 (DE-604)BV000613725 37,2 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016570398&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Eosinophilic and autoimmune gastrointestinal disease new insights and new entities Gastroenterology clinics of North America Autoimmune Diseases of the Gastrointestinal System Autoimmune diseases Celiac Disease Eosinophil disorders Eosinophils pathology Esophagitis Gastroenteritis Gastrointestinal Diseases Gastrointestinal Motility Gastrointestinal system Diseases Hepatitis, Autoimmune Inflammatory Bowel Diseases Liver Cirrhosis, Biliary Pancreatitis |
| title | Eosinophilic and autoimmune gastrointestinal disease new insights and new entities |
| title_auth | Eosinophilic and autoimmune gastrointestinal disease new insights and new entities |
| title_exact_search | Eosinophilic and autoimmune gastrointestinal disease new insights and new entities |
| title_exact_search_txtP | Eosinophilic and autoimmune gastrointestinal disease new insights and new entities |
| title_full | Eosinophilic and autoimmune gastrointestinal disease new insights and new entities guest ed. Nicholas J. Talley |
| title_fullStr | Eosinophilic and autoimmune gastrointestinal disease new insights and new entities guest ed. Nicholas J. Talley |
| title_full_unstemmed | Eosinophilic and autoimmune gastrointestinal disease new insights and new entities guest ed. Nicholas J. Talley |
| title_short | Eosinophilic and autoimmune gastrointestinal disease |
| title_sort | eosinophilic and autoimmune gastrointestinal disease new insights and new entities |
| title_sub | new insights and new entities |
| topic | Autoimmune Diseases of the Gastrointestinal System Autoimmune diseases Celiac Disease Eosinophil disorders Eosinophils pathology Esophagitis Gastroenteritis Gastrointestinal Diseases Gastrointestinal Motility Gastrointestinal system Diseases Hepatitis, Autoimmune Inflammatory Bowel Diseases Liver Cirrhosis, Biliary Pancreatitis |
| topic_facet | Autoimmune Diseases of the Gastrointestinal System Autoimmune diseases Celiac Disease Eosinophil disorders Eosinophils pathology Esophagitis Gastroenteritis Gastrointestinal Diseases Gastrointestinal Motility Gastrointestinal system Diseases Hepatitis, Autoimmune Inflammatory Bowel Diseases Liver Cirrhosis, Biliary Pancreatitis |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016570398&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000613725 |
| work_keys_str_mv | AT talleynicholasj eosinophilicandautoimmunegastrointestinaldiseasenewinsightsandnewentities |